AR and prostate carcinoma: Reducing gonadal testosterone levels continues to be a cornerstone of treatment for advanced prostate cancer, as the majority of tumors express androgen receptors (AR), underscoring the central role of androgen signaling in prostate cancer pathogenesis [123, 124].